Epigen Biosciences is focused on the discovery and development of small-molecule drugs targeting various serious medical conditions. The company is advancing a selective LPA1 antagonist aimed at treating diabetic kidney disease (DKD), non-alcoholic steatohepatitis (NASH), and idiopathic pulmonary fibrosis (IPF). DKD is a significant health issue, with millions affected and rising prevalence expected. NASH, a severe liver disease linked to obesity and diabetes, currently lacks effective treatments. Additionally, Epigen is developing sigma-1 receptor (S1R) ligands that may offer therapeutic potential for Alzheimer's disease and amyotrophic lateral sclerosis (ALS), both of which are neurodegenerative disorders with limited treatment options.

Furthermore, Epigen is exploring p70 S6 kinase inhibitors for fragile X syndrome (FXS), a genetic condition that leads to cognitive impairment. The company has identified a target that regulates protein synthesis, which is crucial for learning and memory, and is developing small-molecule inhibitors to address the underlying causes of FXS. Additionally, Epigen is investigating PAM-II compounds for stroke and traumatic brain injury (TBI), leveraging their ability to activate the alpha-7 nicotinic acetylcholine receptor (a7 nAChR) to enhance cognitive function and provide neuroprotection. Through a collaborative approach and advanced drug discovery techniques, Epigen aims to bridge the gap between lead identification and clinical proof-of-concept, expediting the development of innovative therapies for unmet medical needs.

United States

Epigen employs hit-to-lead and lead optimization techniques. These encompass computational design, scaffold-hopping, focused library synthesis, and screening. They use in silico drug discovery tools, coupled with property assessment for Absorption, Distribution, Metabolism, and Excretion (ADME). These methodologies and processes scrutinize parameters such as physicochemical attributes, solubility, metabolic stability, CYP450 inhibition, hERG liability, oral bioavailability, central nervous system (CNS) permeation, toxicology, and in vivo effectiveness.

Epigen Biosciences

Company Details